130 related articles for article (PubMed ID: 18824850)
1. Somatostatin elevates topoisomerase II alpha and enhances the cytotoxic effect of doxorubicin on gallbladder cancer cells.
Quan ZW; Yue JN; Li JY; Qin YY; Guo RS; Li SG
Chemotherapy; 2008; 54(6):431-7. PubMed ID: 18824850
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation.
Quan ZW; Yang Y; Li JY; Gong W; Qin YY; Li SG
Biomed Pharmacother; 2010 Sep; 64(7):451-7. PubMed ID: 20359855
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line].
Qin YY; Li JY; Li SG; Yue JN; Quan ZW
Zhonghua Wai Ke Za Zhi; 2008 Mar; 46(5):381-3. PubMed ID: 18785538
[TBL] [Abstract][Full Text] [Related]
5. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration].
Gong W; Qin YY; Li SG; Quan ZW; Li JY; Zhuang PY; Wan ZW
Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2718-22. PubMed ID: 21162905
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
9. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Hohla F; Buchholz S; Schally AV; Krishan A; Rick FG; Szalontay L; Papadia A; Halmos G; Koster F; Aigner E; Datz C; Seitz S
Cancer Lett; 2010 Aug; 294(1):35-42. PubMed ID: 20156671
[TBL] [Abstract][Full Text] [Related]
10. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
[TBL] [Abstract][Full Text] [Related]
11. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E
J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227
[TBL] [Abstract][Full Text] [Related]
12. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
13. The synergistic inhibitory effect of somatostatin-doxorubicin co-treatment on gallbladder carcinoma.
Li JY; Quan ZW; Zhang Q; Liu JW
BMC Cancer; 2007 Jul; 7():125. PubMed ID: 17617924
[TBL] [Abstract][Full Text] [Related]
14. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
Lasfer M; Vadrot N; Schally AV; Nagy A; Halmos G; Pessayre D; Feldmann G; Reyl-Desmars FJ
J Hepatol; 2005 Feb; 42(2):230-7. PubMed ID: 15664249
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of liver metastasis model of human gallbladder cancer and isolation of the subpopulation with high metastatic potential].
Liu YB; He XW; Wang JW; Li JT; Li KQ; Liu FB; Xue JF; Zhu JH; Li B; Peng SY
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(30):2117-21. PubMed ID: 17064616
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
Shi P; Wang MM; Jiang LY; Liu HT; Sun JZ
Chin Med J (Engl); 2008 Oct; 121(20):1975-9. PubMed ID: 19080259
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
Pozsgai E; Schally AV; Halmos G; Rick F; Bellyei S
Horm Metab Res; 2010 Oct; 42(11):781-6. PubMed ID: 20665426
[TBL] [Abstract][Full Text] [Related]
18. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
Toyoda E; Kurosawa A; Kamekawa H; Adachi N
Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
